Skip to main content

Table 1 Clinical characteristic

From: Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy

Clinical information Group I(81) Group II (44) P-value
General information
 Sex (female/male) 36/45 22/22 0.552
 Age, years 6.54 ± 3.03 7.61 ± 2.49 0.031
 Weight, kg 20.4 (16.4, 28.9) 27.2 (20.0, 33.5) 0.002
Clinical presentation n (%)
 Fever 81 (100%) 44 (100%) 1.00
 Cough 75 (92.6%) 43 (97.7%) 0.891
 Hypoxemia 6 (7.41%) 28 (63.6%) 0.000
 respiratory failure 0 2 (4.55%) 0.041
 Extra-pulmonary complications 18 (22.2%) 33 (75.0%) 0.007
 Thromboembolism 2 (2.47%) 2 (4.55%) 0.613
total fever duration, days 11 (8, 13) 13 (11, 15) 0.000
preadmission fever duration, days 7 (5, 8) 6 (4, 7) 0.329
fever duration at the time of CS treatmenta, days 1.95 ± 1.91 5.45 ± 2.76 0.000
Length of stay, days 8 (7, 10) 13.5 (11.3, 16) 0.000
Management
 Hormone dose, mg/kg/day 2 (1.5, 2) 10 (8.5, 10) 0.000
 Gamma globulin, n (%) 9 (11.1%) 17 (38.6%) 0.000
 Bronchoscopy, n (%) 57 (70.4%) 41 (93.2%) 0.000
 Plastic bronchitis, n (%) 14 (17.3%) 29 (65.9%) 0.000
  1. Data are presented as number (percentage), median (25th–75th percentile). Data are presented as mean ± SD (x ± s)
  2. aThe meaning of fever duration at the time of corticosteroids treatment is that fever days after starting corticosteroids therapy